Pulse Biosciences Inc ( (PLSE) ) has released its Q1 earnings. Here is a breakdown of the information Pulse Biosciences Inc presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pulse Biosciences, Inc., a bioelectric medicine company, specializes in the development of its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for medical applications, particularly in the treatment of atrial fibrillation and soft tissue ablation. In its first quarter 2025 earnings report, the company highlighted several strategic advancements, including the expansion of commercial resources for its nsPFA Percutaneous Electrode and the initiation of clinical trials for its cardiac surgery and catheter systems. Financially, Pulse Biosciences reported an increase in both GAAP and non-GAAP expenses due to stock-based compensation and organizational expansion, resulting in a net loss for the quarter. Despite these losses, the company maintains a strong cash position, bolstered by proceeds from warrant exercises. Looking ahead, Pulse Biosciences is poised to advance its clinical trials and commercial efforts, with plans to launch new products and expand its market presence in the latter half of 2025.